Sanofi-Aventis and Lilly in Cialis marketing pact

Share this article:
Sanofi-Aventis has teamed with Eli Lilly in a collaboration to market erectile-dysfunction drug Cialis (tadalafil) to US urologists. 

According to Lilly spokesperson Lee Lang, the campaign hopes to “educate urologists nationwide by providing direct selling support for 2.5 mg and 5 mg doses, as well as for use on an ‘as needed' basis.” Lang explains the decision, noting Sanofi's “strong market position in urology.”
Sanofi-Aventis spokeswoman Noelle Boyd added, “Our sales force has developed trust among urologists over the years.” Sanofi-Aventis markets Uroxatral (alfuzosin HCI), for benign prostatic hyperplasia (BPH), and Taxotere (docetaxel), a chemotherapy indicated for prostate cancer, to urologists.

The partnership follows FDA approval in January for a once-daily use in 2.5 mg and 5 mg doses.  Cialis is also known as the “36 hour pill” or the “weekend pill,” due to its longer duration of action in patients. 

A spokesperson for Lilly told CNNMoney that the collaboration with Sanofi-Aventis began on March 13.  On the consumer side, Cialis was recently ranked second in the Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests, according to a Manhattan Research study. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions